Lantos tours local biotech firm, hears concerns

Officials with Monogram Biosciences say a number of legislative pressures are hindering their ability to recoup costs and attract the top talent they need to survive.

Monogram has spent the past seven years providing individualized drug combinations to HIV-positive patients, and hopes to expand its technology into treating various types of cancer, according to CEO William Young. Congressman Tom Lantos, D-San Mateo, visited the lab Wednesday and heard Young's concerns, which include low levels of reimbursement for diagnostic firms, legislators' increasing zeal to regulate the biotech market and the elimination of relationships between private biotech companies and researchers working for the National Institutes of Health.

“This is a cutting-edge company,” Lantos said in support of Monogram's mission. “I think there are enormous possibilities for this kind of individualized approach to medicine.”

As representative for San Mateo County and parts of San Francisco, Lantos said he keeps a close eye on the medical and biotech world. He is an avid supporter of embryonic stem-cell research and, in 2002, co-authored a bill that raised $3.3 billion to fight HIV/AIDS, malaria and tuberculosis.

During Wednesday's tour of Monogram's laboratories, Lantos asked what skills are required to land a job at a firm like Monogram.

Most clinicians have a state-issued clinical laboratory license or at least a bachelor of science degree, according to Linda Kiss, Director of Process Development. Because many clinicians are required to obtain a state license, it's difficult to attract top talent — a fact that may force some biotech firms to relocate to other parts of the country, according to Young.

With 150 biotech firms in South San Francisco alone, “the demand for scientifically trained people is an issue,” Young said. Some work full-time at one firm and part-time at another to fill the gaps, he added.

Although Lantos joked about a brief stint in medical school — one that lasted until he saw his first cadaver — his granddaughter has been diagnosed with a rare lung disorder, piquing his interest in the medical world, he said.

businessLocalScience & TechnologyScience and Technology

If you find our journalism valuable and relevant, please consider joining our Examiner membership program.
Find out more at www.sfexaminer.com/join/

Just Posted

Diners at Teeth, a bar in the Mission District, on July 9, 2021. Teeth began using digital menus based on QR code technology in August. (Ulysses Ortega/The New York Times)
The football stadium at UC Berkeley, on Saturday, Sept. 26, 2020. George Kliavkoff, a former top executive at MGM Resorts International, took over the conference at the start of the month. (Jim Wilson/The New York Times)
What’s Ahead for the Pac-12? New commissioner weighs in

‘Every decision we make is up for discussion. There are no sacred cows.’

The sidewalk on Egbert Avenue in the Bayview recently was cluttered with car parts, tires and other junk. <ins>(Kevin N. Hume/The Examiner)</ins>
New surveillance effort aims to crack down on illegal dumping

’We want to make sure we catch people who are trashing our streets’

As the world reeled, tech titans supplied the tools that made life and work possible. Now the companies are awash in money and questions about what it means to win amid so much loss. (Nicolas Ortega/The New York Times)
How tech won the pandemic and now may never lose

By David Streitfeld New York Times In April 2020, with 2,000 Americans… Continue reading

Most Read